Loading...
Market
Which company will first receive FDA approval for a competitor to AUCATZYL® (obe-cel) by end of 2025?
2
Resolution / Starting Odds
Novartis • 25%
Gilead Sciences • 25%
Bristol Myers Squibb • 25%
Other • 25%
FDA approval announcements
Story
Autolus Therapeutics Gains FDA Approval for AUCATZYL® (obe-cel) CAR-T Therapy in Leukemia
Nov 11, 2024, 12:14 PM
Autolus Therapeutics has received FDA approval for its CAR-T therapy, AUCATZYL® (obecabtagene autoleucel – obe-cel), for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This marks the first product approval for the UK-based biotech company. Autolus stock rose 9.9% pre-market following the announcement.
View original story
Similar markets
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
AbbVie • 25%
Bristol Myers Squibb • 25%
Another major pharmaceutical company • 25%
No new approvals • 25%
Another cancer therapy • 25%
A non-cancer therapy • 25%
No new approvals • 25%
Other • 25%
1-2 • 25%
3-4 • 25%
5-6 • 25%
More than 6 • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%